Business Context and Reporting Period
Company: Incyte Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1999
Business Overview: Incyte designs, develops, and markets genomic information-based products, including databases, software tools, microarray-based gene expression services, and genomic reagents. The company operates primarily in one reportable segment focused on drug discovery and development tools for the pharmaceutical and biotechnology industries.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 1999 | Nine Months Ended Sep 30, 1999 | Nine Months Ended Sep 30, 1998 |
|---|---|---|---|
| Revenues | $35,415 | $110,938 | $98,164 |
| Net Income (Loss) | $(11,066) | $(20,363) | $1,987 |
| Net Loss Per Share (Diluted) | $(0.39) | $(0.73) | $0.07 |
| Research & Development Expenses | $36,874 | $104,240 | $69,581 |
| Cash and Cash Equivalents (Sep 30, 1999) | $41,388 | ||
| Marketable Securities (Sep 30, 1999) | $40,675 | ||
| Total Current Assets (Sep 30, 1999) | $98,915 | ||
| Total Current Liabilities (Sep 30, 1999) | $43,788 | ||
| Accumulated Deficit (Sep 30, 1999) | $(48,764) |
Cash Flow (Nine Months Ended Sep 30, 1999):
- Net cash used in operating activities: $(4,677) thousand
- Net cash used in investing activities: $(9,265) thousand
- Net cash provided by financing activities: $5,340 thousand
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased to $110.9 million for the nine months ended September 30, 1999, compared to $98.2 million in the prior year period. This growth was driven by expanded collaborative database agreements and increased microarray-based gene expression services.
- Shift to Net Loss: The company reported a net loss of $20.4 million for the nine months ended September 30, 1999, compared to a net income of $2.0 million in the same period in 1998. The 1998 results included a one-time $11.0 million charge for in-process research and development related to the Hexagen acquisition, which was not present in 1999.
- Expense Increases: Research and development expenses rose significantly to $104.2 million (nine months 1999) from $69.6 million (nine months 1998), reflecting heavy investment in genomic sequencing, bioinformatics, and SNP discovery programs. Selling, general, and administrative expenses also increased to $26.9 million, partly due to legal expenses of approximately $5.1 million related to patent litigation.
- Joint Venture Losses: The company recorded losses from its joint venture, diaDexus, LLC, totaling $4.4 million for the nine months ended September 30, 1999, compared to $0.6 million in the prior year.
Guidance, Outlook, and Risks
Outlook and Guidance:
- The company expects to continue incurring net losses through at least the second quarter of 2000 due to significant investments in genomic sequencing, mapping, and SNP discovery.
- Management anticipates a return to profitability in the second half of 2000, though profitability for the full year is not guaranteed.
- The company expects to return to generating positive cash flows from operations in 2000.
Material Risks and Contingencies:
- Patent Litigation: Incyte is defending against lawsuits filed by Affymetrix, Inc., alleging infringement of microarray patents. The company cannot estimate the potential loss but notes substantial legal expenses and diversion of management resources. A preliminary injunction was denied in April 1999, with trial scheduled for September 2000. Additionally, the Board of Patent Appeals and Interferences ruled against Incyte regarding patent priority in September 1999; Incyte intends to appeal.
- Acquisition Integration: Risks associated with integrating Hexagen Limited (acquired in 1998) and Synteni, Inc. (acquired in 1998), including potential impairment of goodwill and intangible assets.
- Year 2000 Compliance: The company is evaluating Year 2000 readiness for its systems and vendors. Estimated total costs are between $1.0 million and $1.5 million. Failure of critical systems or vendors could disrupt operations.
- Market Competition: Intense competition in the genomics sector, including public availability of human genome data by the Human Genome Project and Celera Genomics, which could reduce the value of Incyte's proprietary databases.
Key Facts for Investor Verification
- Liquidity Position: Verify the adequacy of cash and marketable securities ($82.1 million total) to fund operations through 2000 given the projected net losses and high capital expenditure requirements ($27.8 million in the first nine months of 1999).
- Litigation Exposure: Monitor the status of the Affymetrix patent infringement lawsuits and the outcome of the appeal regarding the Board of Patent Appeals and Interferences decision, as an adverse outcome could result in injunctions or significant damages.
- R&D Burn Rate: Assess the sustainability of the $104.2 million R&D spend for the nine-month period and the timeline for commercializing SNP discovery and genomic sequencing technologies.
- Revenue Concentration: Review the dependency on database collaboration agreements and the risk of non-renewal or termination of these contracts, which form the primary revenue stream.
- Joint Venture Performance: Track the financial performance of diaDexus, LLC, which contributed $4.4 million to the net loss in the first nine months of 1999.